Company name Intra-Cellular Therapies, Inc.
Stock symbol ITCI
Class period August 12, 2015 and April 28, 2017
Lead plaintiff deadline July 11, 2017
Court Eastern District of New York
Status Under Investigation

NEW YORK, May 16, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who acquired Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) securities between August 12, 2015 and April 28, 2017 (the “Class Period”).

The Complaint states that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) consequently, Intra-Cellular’s public statements were materially false and misleading at all relevant times.

On August 4, 2016, Intra-Cellular’s CEO Sharon Mates specified during an earnings call that “our studies to-date supports the efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular revealed that U.S. Food and Drug Administration had requested further information to verify that the findings observed in nonclinical animal toxicology studies of lumateperone are not suggestive of a safety risk associated with long term exposure in humans. Following this news, Intra-Cellular stock dropped.

If you purchased or otherwise acquired Intra-Cellular securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Join the action by filling out the form below

First name*

Last name*

City, state ZIP code*

Email address*

Daytime phone*

Evening phone

Purchase Date*

No. of Shares*

Purchase Price*

Purchase Date

No. of Shares

Purchase Price

Join action?*
YesNo


Call to provide more information: Tel: (212) 308-5858

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.